Compare NUVL & GTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | GTLS |
|---|---|---|
| Founded | 2017 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 9.3B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | GTLS |
|---|---|---|
| Price | $96.50 | $206.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 11 |
| Target Price | $135.33 | ★ $203.22 |
| AVG Volume (30 Days) | 449.1K | ★ 2.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.24 |
| Revenue Next Year | $1,165.56 | $6.26 |
| P/E Ratio | ★ N/A | $240.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $104.60 |
| 52 Week High | $113.02 | $208.24 |
| Indicator | NUVL | GTLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 46.04 |
| Support Level | $73.71 | $206.55 |
| Resistance Level | $107.13 | $207.59 |
| Average True Range (ATR) | 3.10 | 0.47 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 21.24 | 48.70 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.